BiOptic (ROCO:6850) Total Equity: NT$451.5 Mil (As of Dec. 2025)


ROCO:6850 BiOptic Inc ROCO:6850
92 GF Score
Price NT$35.00
GF Value NT$44.91
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BiOptic Total Equity?

BiOptic ROCO:6850 92 Total Equity is NT$451.5 Mil as of Dec. 2025. GuruFocus rates ROCO:6850 with a GF Score™ of 92/100 and a GF Value™ of NT$44.91 (Modestly Undervalued). The stock has 4 warning signs investors should review.

BiOptic's total equity for the quarter that ended in Dec. 2025 was NT$451.5 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BiOptic Total Equity Historical Data

* Premium members only.

The historical data trend for BiOptic's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BiOptic Total Equity Chart

BiOptic Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 374.79 427.36 443.21 461.75 451.55

BiOptic Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 443.21 444.11 461.75 454.55 451.55
ROCO:6850
92GF Score
BiOptic Inc ROCO:6850
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BiOptic Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BiOptic's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=576.818-125.269
=451.5

BiOptic's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=576.818-125.269
=451.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$451.5 Mil mean?
BiOptic (ROCO:6850) has a Total Equity of NT$451.5 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for BiOptic and its competitors.
Is BiOptic's Total Equity too high?
BiOptic's current Total Equity is NT$451.5 Mil. Overall, BiOptic has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BiOptic's Total Equity compare to VRTX and REGN?
BiOptic's Total Equity of NT$451.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for BiOptic and its competitors. BiOptic's current Total Equity is NT$451.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BiOptic stock overvalued right now?
Based on GuruFocus' analysis, BiOptic (ROCO:6850) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$44.91, compared to a current price of NT$35.00 — trading 22.1% below its estimated fair value. The current Total Equity is NT$451.5 Mil. BiOptic's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For BiOptic (ROCO:6850), the current Total Equity is NT$451.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BiOptic (ROCO:6850) Overvalued in 2026?

Based on GuruFocus' analysis, BiOptic stock appears to be undervalued. The current stock price of NT$35.00 is trading 22.1% below its estimated GF Value™ of NT$44.91. GuruFocus considers BiOptic to be Modestly Undervalued.

Key valuation signals for ROCO:6850:

  • Total Equity: NT$451.5 Mil
  • GF Value™: NT$44.91 vs. price of NT$35.00 (22.1% below fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6850 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BiOptic Business Description

Address No. 108-3, Minquan Road, 4th Floor, Xindian District, New Taipei, TWN, 23141
BiOptic Inc is a biotechnology instrumentation company that develops scientific products for research and clinical applications. It serves professionals and laboratories dedicated to life science research, clinical diagnostics, pharmaceutical and food industries, animal husbandry, and agriculture, performing diagnostic molecular genetic analyses.
92GF Score

Get the complete analysis for ROCO:6850

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.00
Price
NT$44.91
GF Value